Concomitant Use Of Macugen With Visudyne Appears Safe, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Concomitant use of Pfizer/Eyetech's Macugen (pegatanib) with Novartis/QLT's Visudyne (verteporfin) does not pose safety concerns, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee concluded Aug. 27.
You may also be interested in...
Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration
FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.
Miravant's SnET2 Requires Additional Clinical Trial For Macular Degeneration
FDA needs further confirmation before granting full approval to the photosensitive drug/photodynamic therapy combination, Miravant says. The firm is seeking approval for both predominantly and minimally classic AMD.
Pfizer/Eyetech's Macugen: Advisory Cmte. Wants Long-Term Follow Up
While the committee finds the existing data were sufficient for approval, members call for long-term follow up to address safety concerns and duration of therapy. The committee also recommends labeling address endophthalmitis.